OSE Immunotherapeutics Completes Enrollment in Combi-TED Study
OSE Immunotherapeutics and the FoRT Foundation are excited to announce the successful completion of patient enrollment in their innovative Combi-TED clinical trial. This Phase 2 study evaluates the combination of the therapeutic vaccine Tedopi® with either nivolumab or docetaxel, specifically for patients diagnosed with Non-Small Cell Lung Cancer (NSCLC).
Overview of the Combi-TED Study
The Combi-TED trial has enrolled a total of 105 HLA-A2 positive patients, all of whom are part of a critical exploration of combining Tedopi® with either an anti-PD1 checkpoint inhibitor, nivolumab, or the chemotherapeutic agent docetaxel as a second-line treatment. This treatment path comes after patients have undergone first-line chemo-immunotherapy, aiming to deliver optimized personalized care and therapeutic outcomes for those battling metastatic NSCLC.
Representatives from OSE Immunotherapeutics have articulated the anticipation surrounding this trial, with top-line study results expected to emerge in the latter half of 2026. This timeline allows researchers valuable time to analyze the data rigorously, ensuring robust conclusions regarding the efficacy of this promising combination.
Significance of the Study
Combi-TED is designed as an open-label, randomized three-arm Phase 2 study. It seeks to evaluate not only the safety and efficacy of Tedopi® in combination with nivolumab or docetaxel but also the overall survival rates in patients who are HLA-A2 positive and have shown no evidence of EGFR mutations or ALK or ROS1 rearrangement after initial treatment.
As such, the primary endpoint of this clinical trial focuses on the one-year survival rates of participants, marking a significant milestone in the relentless quest for effective cancer therapies. Achieving this recruitment goal reflects the commitment of OSE Immunotherapeutics and the FoRT Foundation to support individuals facing this arduous illness.
Expert Insights on Combi-TED
Dr. Federico Cappuzzo, the Chief Investigator of the study and Director of Medical Oncology at Cancer Institute Regina Elena, commented on the successful enrollment, stating, "We are fully committed to exploring new therapeutic avenues. The combination of the Tedopi vaccine aims to activate T lymphocytes, potentially enhancing the effects of existing checkpoint inhibitors or chemotherapeutic agents. Our focus is now on analyzing the results which we anticipate will play a significant role in future treatment protocols for NSCLC patients who have limited options following first-line treatments."
Silvia Comis, Chief Clinical and Medical Research Officer of OSE Immunotherapeutics, also expressed her appreciation for the collaborative achievement, thanking Dr. Cappuzzo for steering this critical phase. She noted that the progress made with Tedopi® could change the trajectory for many patients who have exhausted conventional treatment methods.
Innovative Approaches in Cancer Treatment
The ongoing investigation into Tedopi® follows positive outcomes from the previous ATALANTE-1 study, revealing encouraging results for the vaccine as a monotherapy compared to docetaxel. This pivotal trial aims to further understand the relevance and potential of Tedopi® as a combination therapy, emphasizing the adaptability and responsiveness of clinical strategies to the evolving landscape of cancer treatment.
As we move forward, the importance of such studies becomes ever more apparent, affirming the necessity for new treatment options within the broader metastatic NSCLC landscape. The developments surrounding Combi-TED provide hope and valuable insights into how innovative therapeutic strategies can fulfill unmet clinical needs in oncology.
About OSE Immunotherapeutics
OSE Immunotherapeutics is dedicated to pioneering first-in-class therapies within the realms of immuno-oncology and immuno-inflammation, addressing pressing medical needs that many patients face today and in the future. Through strategic partnerships with leading academic institutions and biopharmaceutical companies, OSE strives to transform medical landscapes by bringing groundbreaking therapeutic solutions to market.
With operational centers between Nantes and Paris and their presence on Euronext, OSE Immunotherapeutics is positioned at the forefront of cancer immunotherapy innovations, continuing to explore possibilities for novel treatments and collaborative research efforts.
Frequently Asked Questions
What is the Combi-TED study?
The Combi-TED study is a Phase 2 clinical trial assessing the therapeutic cancer vaccine Tedopi® combined with nivolumab or docetaxel for Non-Small Cell Lung Cancer patients.
How many patients were enrolled in the Combi-TED study?
A total of 105 HLA-A2 positive patients were enrolled in the study.
What are the anticipated results from the Combi-TED trial?
Top-line results from the clinical trial are expected to be released in the second half of 2026.
Who is leading the Combi-TED study?
Dr. Federico Cappuzzo is the Chief Investigator of the Combi-TED study, representing the Cancer Institute Regina Elena in Rome, Italy.
What is the ultimate goal of the study?
The primary goal is to evaluate the one-year survival rate of patients receiving Tedopi® in combination therapy, providing insight into new treatment strategies for NSCLC.
